<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110907">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01853865</url>
  </required_header>
  <id_info>
    <org_study_id>OPAL</org_study_id>
    <nct_id>NCT01853865</nct_id>
  </id_info>
  <brief_title>Follow-up of Endometrial Cancer Patients</brief_title>
  <acronym>OPAL</acronym>
  <official_title>Follow-up of Endometrial Cancer Patients: A Valuable Medical Intervention or a Dispensable Force of Habit?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Research Unit of General Practice, Odense</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danish Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <authority>Denmark: Danish Dataprotection Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is conducted, to elucidate the value of follow-up examinations in
      endometrial cancer patients. Specifically the objective is to compare hospital-based
      follow-up examinations with instruction in self-referral in stage I endometrial cancer
      patients.

      The investigators hypothesize that the intervention, instruction in self-referral, will:

        -  reduce fear of recurrence

        -  improve quality of life

        -  improve cost-utility

        -  not affect disease-free survival.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2013</start_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Fear of Cancer Recurrence Inventory (questionnaire)</measure>
    <time_frame>change in score between 1, 10 and 34 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)</measure>
    <time_frame>change in score between 1, 10 and 34 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Endometrial cancer Module (EORTC QLQ-EN24)</measure>
    <time_frame>change in score between 1, 10 and 34 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Posttraumatic Growth Inventory</measure>
    <time_frame>change in score between 1, 10 and 34 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D-5L</measure>
    <time_frame>change in score between 1, 10 and 34 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Items on Unmet needs from the &quot;Coherence for cancer patients questionnaire&quot;</measure>
    <time_frame>change in score between 1, 10 and 34 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>3 years following treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of disease recurrence</measure>
    <time_frame>3 years following treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resource use at hospital, primary care and use of medicinal products</measure>
    <time_frame>During the three years following treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Resource use at hospital: will be measured through questionnaires completed by relevant personnel.
Information on resource use at primary care and use medicinal products: will be collected through the National Insurance Register and the Medicinal Product Register respectively.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>Follow-up</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in this arm attend regular follow-up examinations, as is the current standard, at the department of gynecology following surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Self-referral</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Instead of regular follow-up examinations, this group is carefully instructed in alarm symptoms that require contact with a physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Instruction in self-referral</intervention_name>
    <arm_group_label>Self-referral</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with stage I Endometrial Cancer

        Exclusion Criteria:

          -  Dementia or other mental/cognitive impairment

          -  Illiterate in Danish

          -  Treated with adjuvant chemo- and/or radiotherapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mette M Mathiesen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Gynecology, Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ole Mogensen, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Gynecology, Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pernille T Jensen, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Gynecology, Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dorte G Hansen, Lector, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Research Unit of General Practice, Odense University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mette M Mathiesen</last_name>
    <phone>0045 25385665</phone>
    <email>mette.moustgaard.mathiesen@rsyd.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Unit of gynecology, Odense University hospital</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mette M Mathiesen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 10, 2013</lastchanged_date>
  <firstreceived_date>April 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Mette Moustgaard Mathiesen</investigator_full_name>
    <investigator_title>PhD student</investigator_title>
  </responsible_party>
  <keyword>Endometrial cancer</keyword>
  <keyword>Follow-up examination</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Sarcoma, Endometrial Stromal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
